JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
JAMA Network - Un pódcast de The JAMA Network
Categorías:
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.
